Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan: A Systematic Review and Meta-Analysis.
Journal
Journal of diabetes research
ISSN: 2314-6753
Titre abrégé: J Diabetes Res
Pays: England
ID NLM: 101605237
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
10
2021
revised:
10
01
2022
accepted:
26
01
2022
entrez:
4
3
2022
pubmed:
5
3
2022
medline:
29
3
2022
Statut:
epublish
Résumé
Ramadan is the sacred month of the Islamic Hijri (lunar) calendar, and during this entire month, healthy adult Muslims abstain from eating and drinking from dawn to sunset. Muslims with Type 2 Diabetes Mellitus (T2DM) who choose to fast during Ramadan encounter major risks such as hypoglycemia, hyperglycemia, diabetic ketoacidosis, dehydration, and thrombosis. Although patients with poor glycemic control and on multiple insulin injections are at high risk and exempt from fasting, many still insist on it. Thus, healthcare professionals play a pivotal role in managing diabetes-related complications in patients who fast during Ramadan. However, there is a lack of standard guidelines to be followed in association with structured education and administration of drugs and dosage. Therefore, we performed a systematic review and meta-analysis of the literature to determine the safety and efficacy of different classes of drugs and the importance of structured education during Ramadan. In this review, an extensive PubMed search was performed to obtain literature on T2DM patients who fast during the month of Ramadan until the year 2020. Preference was given to fully downloadable articles. The articles were extracted based on the eligibility criteria. The extracted data were analyzed using Review Manager software version 5.3. A total of 32 articles were included for the review and 7 studies for meta-analysis. Majority of the studies demonstrated the importance of structured education either as a group session or as a one-on-one session with the healthcare professionals in preventing diabetes-related risks during Ramadan. As far as glucose-lowering drugs are concerned, DPP-4 inhibitor combined with metformin remains the drug of choice for T2DM patients who fast during Ramadan. The newer class of glucose-lowering agents appear to lower the risk of hypoglycemia in comparison with sulphonylureas, while among sulphonylureas gliclazide is relatively safe. The meta-analysis indicates that DPP-4 inhibitors would significantly reduce the risk of hypoglycemia as compared to sulphonylurea (odds ratio = 0.38, 95% CI: 0.26 to 0.55, The results of our systematic review show that structured education and counselling by healthcare professionals can be an effective tool in preventing complications associated with fasting during Ramadan in people with T2DM. Additionally, the safest class of oral glucose-lowering drugs preferred during Ramadan fasting in T2DM patients is DPP-4 inhibitors.
Sections du résumé
BACKGROUND
BACKGROUND
Ramadan is the sacred month of the Islamic Hijri (lunar) calendar, and during this entire month, healthy adult Muslims abstain from eating and drinking from dawn to sunset. Muslims with Type 2 Diabetes Mellitus (T2DM) who choose to fast during Ramadan encounter major risks such as hypoglycemia, hyperglycemia, diabetic ketoacidosis, dehydration, and thrombosis. Although patients with poor glycemic control and on multiple insulin injections are at high risk and exempt from fasting, many still insist on it. Thus, healthcare professionals play a pivotal role in managing diabetes-related complications in patients who fast during Ramadan. However, there is a lack of standard guidelines to be followed in association with structured education and administration of drugs and dosage. Therefore, we performed a systematic review and meta-analysis of the literature to determine the safety and efficacy of different classes of drugs and the importance of structured education during Ramadan.
METHODS
METHODS
In this review, an extensive PubMed search was performed to obtain literature on T2DM patients who fast during the month of Ramadan until the year 2020. Preference was given to fully downloadable articles. The articles were extracted based on the eligibility criteria. The extracted data were analyzed using Review Manager software version 5.3.
RESULTS
RESULTS
A total of 32 articles were included for the review and 7 studies for meta-analysis. Majority of the studies demonstrated the importance of structured education either as a group session or as a one-on-one session with the healthcare professionals in preventing diabetes-related risks during Ramadan. As far as glucose-lowering drugs are concerned, DPP-4 inhibitor combined with metformin remains the drug of choice for T2DM patients who fast during Ramadan. The newer class of glucose-lowering agents appear to lower the risk of hypoglycemia in comparison with sulphonylureas, while among sulphonylureas gliclazide is relatively safe. The meta-analysis indicates that DPP-4 inhibitors would significantly reduce the risk of hypoglycemia as compared to sulphonylurea (odds ratio = 0.38, 95% CI: 0.26 to 0.55,
CONCLUSION
CONCLUSIONS
The results of our systematic review show that structured education and counselling by healthcare professionals can be an effective tool in preventing complications associated with fasting during Ramadan in people with T2DM. Additionally, the safest class of oral glucose-lowering drugs preferred during Ramadan fasting in T2DM patients is DPP-4 inhibitors.
Identifiants
pubmed: 35242880
doi: 10.1155/2022/3846253
pmc: PMC8886741
doi:
Substances chimiques
Hypoglycemic Agents
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3846253Informations de copyright
Copyright © 2022 Rashmi Shiju et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Diabetes Metab. 2011 Nov;37(5):395-402
pubmed: 21478041
Can J Diabetes. 2019 Feb;43(1):3-12
pubmed: 29804943
J Pak Med Assoc. 2014 Nov;64(11):1297-302
pubmed: 25831650
Sci Rep. 2017 Aug 31;7(1):10119
pubmed: 28860546
J Diabetes Res. 2016;2016:6962574
pubmed: 27642611
Diabetes Care. 2004 Oct;27(10):2306-11
pubmed: 15451892
Ann Saudi Med. 2011 Jul-Aug;31(4):402-6
pubmed: 21727749
Cleve Clin J Med. 2017 May;84(5):352-356
pubmed: 28530893
Singapore Med J. 2017 May;58(5):246-252
pubmed: 27121922
Diabetes Care. 2004 Nov;27(11):2628-35
pubmed: 15504997
Diabetes Care. 2012 May;35(5):e37
pubmed: 22517945
Diabetes Care. 2010 Aug;33(8):1895-902
pubmed: 20668157
World J Diabetes. 2013 Dec 15;4(6):358-64
pubmed: 24379927
J Assoc Physicians India. 2019 Sep;67(9):70-77
pubmed: 31561693
BMJ. 2010 Jun 22;340:c3053
pubmed: 20570867
Diabetes Spectr. 2017 Aug;30(3):202-210
pubmed: 28848315
Eur Rev Med Pharmacol Sci. 2014 Nov;18(22):3528-33
pubmed: 25491633
Diabetes Care. 1998 Nov;21(11):2033-4
pubmed: 9802768
Diabetes Obes Metab. 2016 Jun;18(6):628-32
pubmed: 26889911
Nutr J. 2011 Aug 10;10:84
pubmed: 21831261
Int J Clin Pract. 2017 Oct;71(10):
pubmed: 28851109
BMJ Open Diabetes Res Care. 2020 May;8(1):
pubmed: 32366501
Arch Med Sci. 2015 Aug 12;11(4):840-8
pubmed: 26322096
Diabetes Res Clin Pract. 2019 Apr;150:282-287
pubmed: 30633934
Diabetes Obes Metab. 2015 Jul;17(7):639-48
pubmed: 25777247
Diabetes Metab Res Rev. 2010 Nov;26(8):606-10
pubmed: 20939000
Diabetes Res Clin Pract. 2017 Apr;126:303-316
pubmed: 28347497
Int J Clin Pract. 2011 Nov;65(11):1132-40
pubmed: 21951832
Front Endocrinol (Lausanne). 2017 Jan 24;8:6
pubmed: 28167928
Diabetes Obes Metab. 2016 Oct;18(10):1025-33
pubmed: 27376711
Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1303-1312
pubmed: 28387897
Diabetes Care. 2014;37(3):e47-8
pubmed: 24558082
Vasc Health Risk Manag. 2014;10:15-24
pubmed: 24391442
J R Soc Med. 2010 Apr;103(4):139-47
pubmed: 20382905
Ther Adv Endocrinol Metab. 2014 Feb;5(1):3-9
pubmed: 24696775
BMJ Open Diabetes Res Care. 2015 Jun 16;3(1):e000111
pubmed: 26113984
Med J Malaysia. 2011 Dec;66(5):447-50
pubmed: 22390099
Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):577-96
pubmed: 26425465
Diabetes Res Clin Pract. 2007 Feb;75(2):141-7
pubmed: 16815586
Diabetes Care. 2005 Feb;28(2):421-2
pubmed: 15677804
Nepal J Epidemiol. 2020 Sep 30;10(3):878-887
pubmed: 33042591
Diabetes Ther. 2014 Dec;5(2):355-66
pubmed: 25424969
J Clin Invest. 2000 Dec;106(11):1305-7
pubmed: 11104782
Diabetes Res Clin Pract. 2018 Jan;135:218-226
pubmed: 29183844
Arch Med Sci. 2013 Oct 31;9(5):936-43
pubmed: 24273582
Int J Clin Pract. 2013 Oct;67(10):957-63
pubmed: 24001317
Int J Health Policy Manag. 2014 Apr 03;2(3):109-14
pubmed: 24757686
J Indian Med Assoc. 2005 Aug;103(8):444-6
pubmed: 16363203
BMJ. 1993 Jul 31;307(6899):292-5
pubmed: 8374375
Diabetes Res Clin Pract. 2018 Oct;144:171-176
pubmed: 30213773
Diabetes Metab Syndr Obes. 2016 Jul 26;9:225-31
pubmed: 27555791
Curr Pharm Des. 2015;21(25):3606-20
pubmed: 26166608
Diabetes Care. 2014 Apr;37(4):e68-9
pubmed: 24652733
BMJ Open Diabetes Res Care. 2015 Jun 16;3(1):e000108
pubmed: 26113983
Diabetes Metab Syndr. 2019 Mar - Apr;13(2):1413-1429
pubmed: 31336501
Acta Diabetol. 2009 Mar;46(1):63-5
pubmed: 18825302
Expert Opin Pharmacother. 2015;16(13):1959-81
pubmed: 26255950
Diabetes Ther. 2013 Dec;4(2):385-98
pubmed: 23996548
Diabetes Res Clin Pract. 2003 Feb;59(2):137-43
pubmed: 12560163
Curr Med Res Opin. 2017 Jan;33(1):161-167
pubmed: 27684469
Int J Environ Res Public Health. 2019 Feb 11;16(3):
pubmed: 30754675
J Assoc Physicians India. 2017 Mar;65(3 Suppl):7-15
pubmed: 28832099
Med J Malaysia. 2012 Jun;67(3):353-4; quiz 355
pubmed: 23082439
Ann Acad Med Singap. 2015 Jun;44(6):202-6
pubmed: 26292948
Int J Environ Res Public Health. 2019 Aug 17;16(16):
pubmed: 31426529
Medicine (Baltimore). 2016 Jan;95(2):e2457
pubmed: 26765440
Sudan J Paediatr. 2017;17(2):11-20
pubmed: 29545660
Am Fam Physician. 2015 May 1;91(9):641-2
pubmed: 25955739
Vasc Health Risk Manag. 2014 May 28;10:319-26
pubmed: 24920915
J Sports Sci. 2012;30 Suppl 1:S9-19
pubmed: 22742901
Med J Malaysia. 2006 Mar;61(1):28-35
pubmed: 16708731
Isr Med Assoc J. 2017 May;19(5):269-274
pubmed: 28513111